| Literature DB >> 30642682 |
Peter Kühnen1, Heiko Krude2, Heike Biebermann2.
Abstract
The melanocortin-4 receptor (MC4R) - embedded in the leptin-melanocortin pathway - is activated by proopiomelanocortin (POMC)-derived neuropeptides such as α- and β-melanocyte-stimulating hormone (MSH) and plays an important role in hypothalamic body-weight regulation. Accordingly, MC4R is a potential drug target to combat obesity. Previous attempts to develop MC4R agonists failed due to ineffectiveness or severe adverse events. Recently, a new generation of MC4R ligands was developed. Specifically, setmelanotide was found to be effective by inducing biased signalling of the MC4R and thereby reducing feelings of hunger and leading to substantial weight loss in patients with POMC or leptin receptor deficiency. This new potential pharmacological treatment option could be beneficial for further groups of obese patients with defects in the leptin-melanocortin signalling pathway.Entities:
Keywords: MC4R; mutation; obesity; signalling; treatment
Year: 2019 PMID: 30642682 DOI: 10.1016/j.molmed.2018.12.002
Source DB: PubMed Journal: Trends Mol Med ISSN: 1471-4914 Impact factor: 11.951